Insider Selling: OrthoPediatrics Corp. (NASDAQ:KIDS) CEO Sells 6,620 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the transaction, the chief executive officer now directly owns 319,155 shares in the company, valued at approximately $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

OrthoPediatrics Stock Performance

Shares of OrthoPediatrics stock traded down $0.57 on Friday, reaching $24.97. The stock had a trading volume of 299,893 shares, compared to its average volume of 162,897. The business's 50-day moving average price is $24.85 and its two-hundred day moving average price is $25.48. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. OrthoPediatrics Corp. has a fifty-two week low of $21.02 and a fifty-two week high of $35.99. The stock has a market cap of $606.45 million, a P/E ratio of -20.30 and a beta of 1.22.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The business had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. On average, sell-side analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Remove Ads

Analysts Set New Price Targets

A number of analysts have issued reports on KIDS shares. Needham & Company LLC reiterated a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a research note on Wednesday, March 5th. Stifel Nicolaus reduced their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Finally, Truist Financial reduced their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Wednesday, December 18th.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors and hedge funds have recently bought and sold shares of KIDS. Quarry LP bought a new position in OrthoPediatrics during the third quarter worth $25,000. R Squared Ltd bought a new stake in OrthoPediatrics in the 4th quarter valued at $48,000. KLP Kapitalforvaltning AS bought a new stake in OrthoPediatrics in the 4th quarter valued at $79,000. BNP Paribas Financial Markets increased its holdings in OrthoPediatrics by 125.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock valued at $94,000 after buying an additional 1,929 shares during the period. Finally, Quantbot Technologies LP increased its holdings in OrthoPediatrics by 42.2% in the 3rd quarter. Quantbot Technologies LP now owns 5,773 shares of the company's stock valued at $157,000 after buying an additional 1,712 shares during the period. Institutional investors own 69.05% of the company's stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.